Dystrobrevin (DTN)

Dystrobrevin is a member of the dystrophin-related protein family and a critical cytoplasmic component of the dystrophin-associated protein complex (DPC) (Wikipedia, 2024; GeneCards, 2024). It exists in two primary isoforms: alpha (DTNA), which is predominantly expressed in skeletal and cardiac muscle and the central nervous system, and beta (DTNB), which is found in non-muscle tissues such as the brain and kidney (dmd.nl, 2004; Wikipedia, 2024). Dystrobrevin functions as a molecular scaffold, linking the DPC to the intracellular cytoskeleton and recruiting signaling molecules like neuronal nitric oxide synthase (nNOS) and syntrophins to the cell membrane (Stanford.edu, 2002; NIH, 2014). Mutations or deficiencies in dystrobrevin are linked to various pathologies, including muscular dystrophies, left ventricular noncompaction (LVNC), and certain cancers like hepatocellular carcinoma (NIH, 2021; NIH, 2026). While not a traditional target for small-molecule inhibitors, its therapeutic potential is being explored through gene therapies that aim to restore DPC stability and through the use of Vitamin D3, which has been shown to upregulate DTNA expression via the Vitamin D Receptor (VDR) axis (Bioscientifica, 2022). This target is particularly relevant for stabilizing the sarcolemma in Duchenne muscular dystrophy and maintaining cardiac function under stress (NIH, 2014; DMD Warrior, 2025).

Other names

Dystrobrevin alphaDystrobrevin betaDTNADTNBDystrophin-related protein 3DRP3LVNC1D18S892E

Upregulation of DTNA expression via Vitamin D Receptor (VDR) activation to stabilize the dystrophin-associated protein complex (DPC); Recruitment of signaling molecules like nNOS to the sarcolemma